文章：

从端粒和端粒酶的角度理解、诊断和治疗胰腺癌

Understanding, diagnosing, and treating pancreatic cancer from the perspective of telomeres and telomerase 

原文发布日期：2024-04-09 

英文摘要：

Telomerase is associated with cellular aging, and its presence limits cellular lifespan. Telomerase by preventing telomere shortening can extend the number of cell divisions for cancer cells. In adult pancreatic cells, telomeres gradually shorten, while in precancerous lesions of cancer, telomeres in cells are usually significantly shortened. At this time, telomerase is still in an inactive state, and it is not until before and after the onset of cancer that telomerase is reactivated, causing cancer cells to proliferate. Methylation of the telomerase reverse transcriptase (TERT) promoter and regulation of telomerase by lactate dehydrogenase B (LDHB) is the mechanism of telomerase reactivation in pancreatic cancer. Understanding the role of telomeres and telomerase in pancreatic cancer will help to diagnose and initiate targeted therapy as early as possible. This article reviews the role of telomeres and telomerase as biomarkers in the development of pancreatic cancer and the progress of research on telomeres and telomerase as targets for therapeutic intervention. 

摘要翻译：

端粒酶与细胞衰老相关，其存在限制了细胞寿命。端粒酶通过阻止端粒缩短，可延长癌细胞的细胞分裂次数。在成人胰腺细胞中，端粒逐渐缩短，而在癌前病变中，细胞内的端粒通常显著缩短。此时端粒酶仍处于非活跃状态，直至癌症发生前后端粒酶被重新激活，导致癌细胞增殖。端粒酶逆转录酶（TERT）启动子的甲基化以及乳酸脱氢酶B（LDHB）对端粒酶的调控，是胰腺癌中端粒酶再激活的机制。了解端粒和端粒酶在胰腺癌中的作用，将有助于尽早诊断并启动靶向治疗。本文综述了端粒和端粒酶作为生物标志物在胰腺癌发展中的作用，以及端粒和端粒酶作为治疗干预靶点的研究进展。

原文链接：

Understanding, diagnosing, and treating pancreatic cancer from the perspective of telomeres and telomerase